{'fraction_non_alphanumeric': 0.030393325387365912, 'fraction_numerical': 0.02205005959475566, 'mean_word_length': 5.482625482625482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
THE HUMAN CHORIONIC SOMATOMAMMOTROPIN, PLACENTAL CYSTINE‐AMINOPEPTIDASE, PROGESTERONE AND THE URINARY OESTROGENS IN PREGNANCIES COMPLICATED WITH ESSENTIAL HYPERTENSION, MILD OR SEVERE PRE‐ECLAMPSIA

The accuracy of urinary oestriol and serum levels of human placental lactogen (HPL) and heat stable alkaline phosphatase (HSAP) as indicators of foetoplacental function was studied in 76 patients with risk pregnancy. Foetoplacental dysfunction was established after the delivery in 20 patients (intrauterine foetal death, extreme retardation of growth, or when at least two of the following signs were present: pronounced foetal acidosis, abnormal heart function, meconium stained amniotic fluid) and normal foetoplacental function in 50 patients (foetal heart function, birth weight, pH values, amniotic fluid, Apgar score and macroscopic appearance of the placenta normal); 6 patients were excluded as borderline cases. Foetoplacental dysfunction was predicted correctly with the criteria used by plasma HPL in 80%, by urinary oestriol in 70%, by serum HSAP in 47%, and by the complementary use of HPL and oestriol in 90% of the cases. Normal foetoplacental function was predicted correctly by plasma HPL in 94%, by urinary oestriol in 96%, by serum HSAP in 80%, and by the complementary use of oestriol and HPL in 100% of the patients. The probability of foetoplacental dysfunction with a pathological value was 88% with urinary oestriol, 84% with plasma HPL and 100% with the parallel use of oestriol and HPL. A normal value assured undisturbed foetoplacental function in 89% with urinary oestriol, in 92% with plasma HPL and in 96% with the parallel use of oestriol and HPL.